Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot trial of Afamelanotide (SCENESSE) in patients with Hailey‐Hailey Disease (HHD, also known as familial benign pemphigus)

Next Previous
X
Search
Trial Profile

Pilot trial of Afamelanotide (SCENESSE) in patients with Hailey‐Hailey Disease (HHD, also known as familial benign pemphigus)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Pemphigus
  • Focus Therapeutic Use
  • Acronyms CUV010

    • Most Recent Events

    • 18 Jul 2016 Results from this study published in both the New England Journal of Medicine and Photochemisty and Photobiology in 2009, as per Clinuvel Pharmaceuticals media release.
    • 02 Dec 2013 New trial record
    • 28 Oct 2013 Results published in the Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top